Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Leukemia, chronic lymphocytic (CLL)
Stage/Subtype:  stage I chronic lymphocytic leukemia
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 44 for your search:
Start Over
Autologous Peripheral Blood Stem Cell Transplant in Treating Patients with Lymphoma
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT 2004-24, NCI-2010-01414, 0508M72589, 2005LS048, UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Status: Enrolling by invitation
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR100955, NCI-2013-02262, 2012-004225-24, PCI-32765CAN3001, NCT01804686
Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Untreated and Previously Treated Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: UTX-TGR-304, NCI-2016-00375, NCT02612311
Allogeneic Stem Cell Transplant for Chronic Lymphocytic Leukemia (CLL)
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 2012-0249, NCI-2012-01248, NCT01629511
Azacitidine in Treating Patients Undergoing Matched Unrelated Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 201303012, NCI-2012-03105, NCT01747499
Ibrutinib and Obinutuzumab in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 65 and over
Trial IDs: GA101 + Ibrutinib, NCI-2015-02052, 141106, NCT02315768
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-LY-005, NCI-2015-01019, NCT02362035
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: eFT508-0002, NCI-2017-00209, NCT02937675
Combination Study of IPH2201 With Ibrutinib in Patients With Relapsed, Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IPH2201-202, NCI-2017-00298, NCT02557516
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2008-0385, NCI-2009-01510, Celgene # RV-CLL-PI-0223, NCT00628238
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
Status: Enrolling by invitation
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1103-CA, NCI-2011-00986, PCI-32765, NCT01109069
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Genetically Engineered Autologous T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 03712, NCI-2012-03024, NCT01747486
Bendamustine Hydrochloride and Rituximab Followed by Rituximab and Lenalidomide in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: HO11414, NCI-2013-00485, 2012-0638, RV-CLL/ -PI-0689, ML28201, NCT01754857
Treatment for Advanced B-Cell Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 3 to 31
Trial IDs: NYMC-157, NCI-2015-01702, L 10,753, NCT01859819
Safety Study of Cord Blood Units for Stem Cell Transplants
Status: Active
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 130116, NCI-2014-01832, 13-H-0116, NCT01861093
Anti-CD19 Monoclonal Antibody XmAb557 and Lenalidomide in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma or Prolymphocytic Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 80
Trial IDs: OSU-13031, NCI-2013-02082, 2013C0086, NCT02005289
Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC138E, NCI-2014-02373, RV-CL-CLL-PI-003938, NCT02309515
Ixazomib Citrate and Rituximab in Treating Patients with Indolent B-cell Non-Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9571, NCI-2016-00401, 9224, NCT02339922
Nivolumab and Ibrutinib in Treating Patients with Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0931, NCI-2015-00844, NCT02420912
Ex Vivo-activated Autologous Lymph Node Lymphocytes with or without Lenalidomide in Treating Patients with Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 2014-0830, NCI-2015-01546, NCT02530515
Ibrutinib and Vaccine Therapies in Treating Patients with Asymptomatic, High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-15012, NCI-2015-00932, 2015C0098, NCT02518555
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients with Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-0281, NCI-2016-00016, NCT02629809
Cholecalciferol in Treating Patients with Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia with Vitamin D Deficiency
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 556-15, NCI-2015-01502, NCT02553447
Start Over